Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

Imaging the DNA damage response with PET and SPECT

(2017) James C. Knight et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

89 Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma

(2017) Suzanne C. van Es et al.   JOURNAL OF NUCLEAR MEDICINE

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents

(2017) Luke Yongkyu Kwon et al.   MOLECULAR PHARMACEUTICS

Journal watch: diagnostic nanoparticles

(2017) Marina Pöttler et al.   Nanomedicine

PET-based Imaging of Chemokine Receptor 2 in Experimental and Disease-related Lung Inflammation

(2017) Yongjian Liu et al.   RADIOLOGY

PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies

(2017) Loren S. Michel et al.   RADIOLOGY

SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic

(2017) Xiaobo Wang et al.   Oncotarget

MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction

(2016) Lili Ren et al.   Acta Biomaterialia

Antibody drug conjugates: lessons from 20 years of clinical experience

(2016) A. W. Tolcher   ANNALS OF ONCOLOGY

PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET

(2016) Wojciech G. Lesniak et al.   BIOCONJUGATE CHEMISTRY

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy

(2016) Nancy E. Hynes   CANCER RESEARCH

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

Quantitative Imaging in Cancer Clinical Trials

(2016) T. E. Yankeelov et al.   CLINICAL CANCER RESEARCH

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET

(2016) Danielle J. Vugts et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions

(2016) Zhexuan Lin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

(2016) Alex Kim et al.   Expert Opinion on Drug Discovery

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

(2016) Kristopher A. Sarosiek et al.   FEBS Journal

TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers

(2016) Anne M. Schultheis et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma

(2016) Russell Vang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Synthesis of a [18F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer

(2016) Sandun Perera et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET

(2016) G. Vaidyanathan et al.   JOURNAL OF NUCLEAR MEDICINE

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT

(2016) G. A. Ulaner et al.   JOURNAL OF NUCLEAR MEDICINE

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

(2016) E. Wehrenberg-Klee et al.   JOURNAL OF NUCLEAR MEDICINE

Standardized uptake value on 18 F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs

(2016) Tatsuya Yoshida et al.   LUNG CANCER

Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT

(2016) Karen Lam et al.   mAbs

Therapy Monitoring with Functional and Molecular MR Imaging

(2016) Roberto García-Figueiras et al.   Magnetic Resonance Imaging Clinics of North America

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

(2016) Richard Laforest et al.   MOLECULAR IMAGING AND BIOLOGY

Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Imaging biomarker roadmap for cancer studies

(2016) James P. B. O'Connor et al.   Nature Reviews Clinical Oncology

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

18F-nanobody for PET imaging of HER2 overexpressing tumors

(2016) Catarina Xavier et al.   NUCLEAR MEDICINE AND BIOLOGY

Two anti-angiogenic TKI-PET tracers, [ 11 C]axitinib and [ 11 C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents

(2016) Paul Slobbe et al.   NUCLEAR MEDICINE AND BIOLOGY

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

(2016) Ronald J. Schmitt et al.   NUCLEAR MEDICINE COMMUNICATIONS

Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment

(2016) Shigeru Yamaguchi et al.   PLoS One

[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity

(2016) Woosuk Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

(2016) Xiaochun Wang et al.   OncoTargets and Therapy

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy

(2016) Ingrid J.G. Burvenich et al.   Theranostics

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

(2016) Witthawat Ariyawutyakorn et al.   Journal of Cancer

Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

(2016) Viviana De Rosa et al.   EJNMMI Research

Therapeutic Targeting of Autophagy

(2016) Christina G. Towers et al.   EBioMedicine

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

(2015) G. Gebhart et al.   ANNALS OF ONCOLOGY

Optimized time-resolved imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models

(2015) Joost Haeck et al.   Contrast Media & Molecular Imaging

Autophagy in malignant transformation and cancer progression

(2015) L. Galluzzi et al.   EMBO JOURNAL

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model

(2015) Diana Spiegelberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Safety evaluation of olaparib for treating ovarian cancer

(2015) Stephanie Lheureux et al.   Expert Opinion On Drug Safety

Crizotinib in the management of advanced-stage non-small-cell lung cancer

(2015) Herbert H Loong et al.   Future Oncology

TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas

(2015) Brandon-Luke L. Seagle et al.   GYNECOLOGIC ONCOLOGY

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

(2015) Seiji Mabuchi et al.   GYNECOLOGIC ONCOLOGY

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

(2015) Robert J Motzer et al.   LANCET ONCOLOGY

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging

(2015) Vadim Bernard-Gauthier et al.   MOLECULES

Autophagy at the crossroads of catabolism and anabolism

(2015) Jasvinder Kaur et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers

(2015) Loredana Santo et al.   SEMINARS IN ONCOLOGY

Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation

(2015) Evrim Gurpinar et al.   TRENDS IN CELL BIOLOGY

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

(2015) Catherina Willemien Menke-van der Houven et al.   Oncotarget

Radioiodinated PARP1 tracers for glioblastoma imaging

(2015) Beatriz Salinas et al.   EJNMMI Research

Targeting Oncogenic Mutant p53 for Cancer Therapy

(2015) Alejandro Parrales et al.   Frontiers in Oncology

BRAF vs RAS oncogenes: Are mutations of the same pathway equal? Differential signalling and therapeutic implications

(2015) Eftychia Oikonomou et al.   Oncotarget

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

The MAPK pathway across different malignancies: A new perspective

(2014) Mauricio Burotto et al.   CANCER

Molecular Pathways: Exploiting Tumor-Specific Molecular Defects in DNA Repair Pathways for Precision Cancer Therapy

(2014) F. Dietlein et al.   CLINICAL CANCER RESEARCH

Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography

(2014) F. Iommelli et al.   CLINICAL CANCER RESEARCH

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

(2014) S. B. M. Gaykema et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

(2014) Bo Hong et al.   CURRENT DRUG TARGETS

Wild type p53 reactivation: From lab bench to clinic

(2014) Galina Selivanova   FEBS LETTERS

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma

(2014) Judy W King et al.   Future Oncology

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

(2014) Ingrid A. Mayer et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

18F-FDG and 18F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice

(2014) Camilla Bardram Johnbeck et al.   PLoS One

18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer

(2014) Stéphanie Lheureux et al.   Translational Oncology

Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches

(2014) Felix Dietlein et al.   TRENDS IN GENETICS

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

(2013) Federica Tomao et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer

(2013) Nikos Gavalas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055

(2013) Heather G. Keen et al.   MOLECULAR IMAGING AND BIOLOGY

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis

(2012) L. Ouyang et al.   CELL PROLIFERATION

Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?

(2012) Marijke De Saint-Hubert et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence

(2011) S. Novello et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

(2010) Gang Niu et al.   CURRENT DRUG TARGETS

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET

(2009) K. B. Contractor et al.   JOURNAL OF NUCLEAR MEDICINE

Molecular imaging of cell death

(2009) Marijke De Saint-Hubert et al.   METHODS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Bcl-2 family proteins and cancer

(2008) K W Yip et al.   ONCOGENE